This paper explores excessive prices at the intersection between competition law and regulated sectors such as pharma. It was prepared as a background note for the OECD Competition Committee roundtable on “Excessive pricing in pharmaceuticals”, which took place in November 2018.

Currently, there is a lack of consensus amongst OECD Member countries as to how profits should be attributed to a permanent establishment (PE). As a first step in remedying this situation a working hypothesis has been developed as to the preferred approach for attributing profits to the PE. The...

This paper defines conglomerate mergers, setting out the reasons why firms engage in them and lays out the classical theories of harm associated with tying and bundling. It also describes how these theories have been adapted to digital markets, highlighting some of the key efficiencies stemming...

The OECD Competition Committee debated competition policy and efficiency claims in horizontal agreements in November 1995. This document includes an analytical note by the OECD, written submissions from Canada, the European Commission, Italy, Japan, Switzerland, the United States and BIAC and an...